Christina Elisabeth Herder
Chief Executive Officer at IDOGEN AB (PUBL)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Magnus Essand | M | 60 | 10 years | |
Eva Agneta Edberg | F | 68 | 4 years | |
Di Yu | M | 39 | 10 years | |
Hans Peter Bøhn | M | 69 | 9 years | |
Sharon Longhurst | F | - | 4 years | |
Margareth Jorvid | F | 63 | 4 years | |
Ellen Donnelly | M | 50 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | 8 years |
Rolf Ingvar Lenart | M | 68 | 8 years | |
Jan Gustaf Zetterberg | M | 73 | 4 years | |
Jamal El-Mosleh | M | 43 | 10 years | |
Hilde Furberg | F | 65 | 5 years | |
Lars Kåre Viksmoen | M | 75 | 8 years | |
Maria Sofia Ekelund | F | 54 | - | |
Dennis Bang Henriksen | M | 62 | 9 years | |
Han Jing Xie | M | 54 | 2 years | |
Rory Graham | M | - | 2 years | |
Anna Koptina Gültekin | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Leif-Göran Salford | M | 83 | 14 years | |
Karin Hoogendoorn | M | 54 | - | |
Anders Eric Karlsson | M | 59 | 3 years | |
Andrew Hughes | M | - | 5 years | |
Neil Thomas | M | - | 9 years | |
Niklas Wallett | M | 48 | - | |
Joakim Söderström | M | 40 | - | |
Terese Hylander | M | 39 | 3 years | |
Vicki Venizelos | F | - | - | |
Christina Brattström | F | - | 2 years | |
Amir Snapir | M | - | 2 years | |
Ludovic Robin | M | - | 2 years | |
Lena Jendeberg | M | 60 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | - |
Hans Olivecrona | M | 66 | 3 years | |
Johan Georg Harmenberg | M | 70 |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | - |
Gael L'Hévéder | M | 56 | 6 years | |
Åsa Schiött | M | - | 2 years | |
Lennart Svensson | M | 63 | 1 years | |
Vendela Parrow | M | - |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | - |
Kjetil Taskén | M | 59 | 10 years | |
Hilde Hermansen Steineger | M | 58 | 5 years | |
Per Walday | M | 64 | 14 years | |
Mikael Oerum | M | - | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 29 | 72.50% |
Norway | 11 | 27.50% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christina Elisabeth Herder
- Personal Network